Monograph Details
|
|
Neoplasms
> Miscellaneous oncology agents
|
|
ONCASPAR |
| Manufacturer |
|
Enzon Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Enzyme |
| Generic Name |
|
Pegaspargase 750 IU/mL; soln for IV or IM inj; preservative-free. |
| Indications |
|
First-line acute lymphoblastic leukemia (including patients with asparaginase hypersensitivity). |
| Adults and Children |
|
Give by IV inj over 1–2 hours or by IM inj (max 2mL/inj site). 2500 IU/m2 no more frequently than every 14 days. |
| Contraindications |
|
History of pancreatitis, serious hemorrhage, or thrombosis with prior L-asparaginase therapy. |
| Precautions |
|
Have resuscitation equipment available and observe patient for 1 hour post-dose. Monitor coagulation parameters. Discontinue if serious allergic reactions, thrombotic events, or pancreatitis occurs. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, CNS thrombosis, coagulopathy, hyperbilirubinemia, elevated transaminases. |
| How Supplied |
|
Single-use vial (5mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
